A supplement label is a promise. A laboratory report is an observation. Those are two very different kinds of document, and the gap between them is where most of the useful thinking about product quality actually happens.
The label tells you what a manufacturer set out to put in the bottle. It is a statement of intent, drafted before the product existed in its finished form. A laboratory report tells you what a specific sample of the finished product looked like when a specific analytical method was pointed at it, on a specific day, against a specific list of substances. Neither document is a guarantee. Read together, and read honestly, they tell you considerably more than either does alone.
For anyone comparing deer placenta supplements, that distinction is worth understanding properly, because “laboratory tested” is one of the easiest phrases in the industry to print and one of the hardest to interpret.
A Label Is a Declaration, Not a Verification
Product labels carry genuinely useful information: declared ingredients, serving size, directions, warnings, allergen details, and the name of whoever is responsible for the product. What they cannot do is confirm themselves.
This is not a criticism of labelling so much as a description of what labelling is for. As the NIH Office of Dietary Supplements explains to consumers, supplements are not reviewed and approved before they reach the market the way prescription medicines are. The responsibility for substantiating a product’s safety and label accuracy sits with the company selling it. The regulatory model is largely post-market. It relies on manufacturers doing the right thing, and on authorities catching those who do not.
That model works reasonably well most of the time. The point of finished-product testing is to say something about a particular batch rather than about the industry in aggregate.
Adulteration Problem Is Documented, Not Hypothetical
It would be easy to write about undeclared pharmaceutical substances as a theoretical risk. It is not one.
The U.S. Food and Drug Administration maintains a running programme of consumer alerts about products contaminated with hidden ingredients, where the substances involved are frequently prescription drug ingredients, banned compounds or their chemical analogues. The agency is explicit that its own list captures only a fraction of what is on the market, and that absence from the list is not evidence of safety.
The scale has been measured. An analysis published in JAMA Network Open examined the FDA’s tainted supplements database from 2007 to 2016 and identified 776 adulterated products implicating 146 companies, with a fifth of those products containing more than one undeclared ingredient. A separate review in the journal Pharmacy tracked European alerts through the RASFF system between 2011 and 2022 and found that of 982 notifications concerning food supplement composition, 474 involved pharmaceuticals used as adulterants, with roughly two-thirds of the relevant notifications classified as serious risks.
Two things follow from this, and both matter.
The first is that the risk is concentrated. In both datasets, the categories most affected were sexual performance, weight management and sports products, where a fast, obvious physiological effect is exactly what the buyer is paying for and therefore exactly what a dishonest formulator has an incentive to manufacture. Deer placenta supplements do not sit in that high-incentive group.
The second is that low incidence in a category is a statistical observation about a market, not a statement about the bottle in your hand. That is precisely the question finished-product testing exists to address.
Where Deer Placenta Products Sit in This Picture
Deer placenta supplements are animal-derived products sold in a number of markets as part of general wellness routines. This article makes no claims about what they do; that is a separate question with a separate evidence base.
What is relevant here is that formulations vary a great deal. Some products contain deer placenta extract alone. Others combine it with botanical extracts, nutritional oils, vitamins or additional dietary ingredients inside a single softgel. Sourcing, processing and quality systems differ between manufacturers, sometimes substantially.
And the delivery format is opaque, in the literal sense. A capsule or softgel gives up no information to inspection. You cannot look at it, smell it or taste it and learn anything meaningful about its composition. For products like these, documentation is the only window available, which puts a great deal of weight on how honestly that documentation is presented.
Why the Finished Product Is the Unit That Matters
Responsible manufacturing starts long before anything reaches a consumer. Under the dietary supplement good manufacturing practice rules set out in 21 CFR Part 111, manufacturers are expected to establish specifications, qualify suppliers, verify the identity of dietary ingredients and maintain records throughout production. These controls are not optional extras. They are the foundation.
But ingredient-level controls answer an ingredient-level question. They tell you about components at the point they entered the process. They do not tell you about the article that emerged from it after blending, encapsulation and packaging, and they do not close off every route by which something unintended could enter.
Finished-product screening asks a narrower and more practical question: what is in the thing the customer actually receives? For multi-ingredient softgels in particular, that is the more useful question, because it is the only one that examines the combined article rather than its parts.
The two approaches are complements. Testing the finished product does not excuse weak process control, and strong process control does not make finished-product testing redundant.
Screening Panels Are Designed, Not Universal
There is no single analytical method that detects every pharmaceutical compound that could theoretically be present in a supplement. Anyone who implies otherwise is either confused or selling something.
Screening panels are built for a purpose. What goes into one depends on the product category, the way the product is likely to be used, historical patterns of adulteration in comparable products, regulatory alerts, the analytical methods available, and what the client commissioning the work asked for. Depending on the programme, a panel might cover stimulants, corticosteroids, prescription medicines, sedatives, weight management drugs, sexual performance drugs, analgesics, antihistamines and specified chemical analogues of these.
The categories are not interchangeable. Undeclared stimulants raise cardiovascular and nervous system concerns; undeclared corticosteroids raise a different set of questions, particularly around repeated exposure over time. A panel that covers one tells you nothing about the other.
This is why two products can both carry the phrase “laboratory tested” and mean entirely different things by it. The phrase on its own is close to meaningless. The scope document behind it is where the information lives.
“Not Detected” Is a Statement About a Method, Not About Reality
Of all the terms on a certificate of analysis, this is the one most likely to be misread.
“Not detected” does not mean zero. It means the laboratory did not obtain a signal meeting its established criteria for identifying that substance in that sample using that method. Every analytical method has a threshold below which it stops being able to distinguish a real signal from background noise, and the position of that threshold is a property of the method, not of the product.
The Eurachem guide on the fitness for purpose of analytical methods sets out why this is more subtle than it first appears: the probability of detection does not flip from zero to certainty at a single tidy cut-off point, which is why analytical chemists have spent decades arguing about how detection limits should be defined and reported at all.
So a “not detected” result does not establish that every possible pharmaceutical was examined, that the concentration is mathematically zero, that a different batch would give the same result, that any regulator has reviewed the product, or that the product is safe. It establishes something narrower and still genuinely worth having: on this sample, against these substances, using this method, nothing was found above the reporting threshold.
Stating that plainly does not weaken a testing programme. It is the thing that makes the programme credible.
Batch Number Is the Line That Ties It Together
A laboratory report describes the sample that was submitted. That is the whole of its authority.
Which makes batch identification the load-bearing detail. A report worth reading will name the product, the dosage form, the batch or lot number, the testing laboratory, the analytical method, the substances examined, the reporting criteria and the findings. Without a batch reference, a report cannot be connected to anything you can buy, and a claim that “our product is tested” floats free of verification entirely.
Batch-level documentation also creates a record that can be checked against, which is the difference between transparency and the appearance of transparency.
Who Ran the Test, and Under What Accreditation?
The identity and competence of the laboratory matters as much as the result.
The international benchmark here is ISO/IEC 17025, the standard covering the competence of testing laboratories, which addresses impartiality, consistency of operation and the ability to produce valid results. Accreditation to that standard is granted against a defined scope, so the useful question is not simply whether a laboratory is accredited but whether the specific testing being cited falls within what it is accredited to do.
It is also worth knowing where finished-product screening sits relative to full third-party certification. Programmes such as the USP Dietary Supplement Verification Program combine manufacturing facility audits with testing for ingredient identity and quantity, specified contaminants and product performance, and award a mark that appears on the packaging. A screening report for undeclared pharmaceuticals is a narrower instrument than that. It is not a certification, and a company presenting it as one is overstating its hand.
What Honest Publishing Looks Like
Plenty of brands state that a product is tested and stop there, with no indication of what was examined, who examined it, by what method, or how the results should be read.
A smaller number publish the reasoning. That is a meaningful difference, because explaining the limits of your own testing is the sort of thing companies only do when the testing is real. EINNALAB is one example of this approach, having published an explanation of its independent laboratory screening for deer placenta supplements covering analytical scope, batch-specific reporting and how findings should and should not be interpreted, alongside a companion piece on how deer placenta supplements are manufactured and tested.
Educational publishing is not a substitute for accredited laboratory documentation, regulatory oversight or sound manufacturing. It is a signal about how a company thinks. Read it as such, and then look for the documents themselves.
A Short Checklist Before You Buy
If you take nothing else from this, take these five questions:
- Was the finished product tested, or only its ingredients?
- Does the report carry a batch or lot number you can match to what you are buying?
- Which substances were on the panel, and does the scope document actually say?
- Which laboratory did the work, and is that testing within its accreditation scope?
- Does the company explain what “not detected” means, or does it let you assume the stronger version?
A brand that answers all five without being pushed is telling you something. So is one that cannot answer any of them.
Honest Bottom Line
Independent screening for undeclared pharmaceutical substances is a useful, limited instrument. It examines a sample, not a universe. It reports against a panel, not against everything. It describes a batch, not a brand.
Held to what it can actually support, it is one of the more informative things a supplement manufacturer can publish. Stretched into a safety guarantee or a substitute for regulatory approval, it becomes marketing wearing a lab coat.
The buyers who get the most out of these documents are the ones who read them for what they say rather than for the reassurance they hope to find. That habit is worth more than any single certificate, and it applies well beyond deer placenta supplements.